Novel lead series of GRK2 inhibitors for heart failure reported by GSK
Aug. 29, 2022
GSK plc presented data on the discovery of a selective and potent lead series for G protein-coupled receptor kinase 2 (GRK2) inhibition for the potential treatment of heart failure. Heart failure remains a leading cause of morbidity and mortality worldwide.